Prosecution Insights
Last updated: April 19, 2026

Biogen Inc.

5 pending office actions • 2 clients

Portfolio Summary

5
Total Pending OAs
0
Final Rejections
5
Non-Final OAs

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
BIOGEN MA INC. 4
Ionis Pharmaceuticals, Inc. 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18283526 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BIOGEN MA INC. MCKILLOP, JOHN CHARLES 1637 Non-Final OA Sep 22, 2023
18273053 MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS BIOGEN MA INC. GRIZER, CASSANDRA SENN 1672 Non-Final OA Jul 19, 2023
18026772 COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH AAV-MIR-SOD1 BIOGEN MA INC. MCLEOD, AFRICA MHAIRIE 1635 Non-Final OA Mar 16, 2023
17635363 COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY BIOGEN MA INC. MCKILLOP, JOHN CHARLES 1637 Non-Final OA Feb 14, 2022
17291199 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS Ionis Pharmaceuticals, Inc. QIAN, CELINE X 1637 Non-Final OA May 04, 2021

Managing Biogen Inc.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month